---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-030932"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2023-06-22T23:59:59+00:00"
generated_at: "2026-06-13T19:11:38.801075+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Pharma stockholders elect four Class I directors and approve say-on-pay

## Summary
- Four director nominees elected: Momtazee (126.98M for), McCormick (126.13M for), Scott (131.25M for), Valantine (107.39M for); 14.89M broker non-votes.
- Non-binding advisory vote on executive compensation passed with 104.00M for, 29.90M against, 45.6k abstentions.
- Ratification of Deloitte & Touche as auditor for FY2023 approved with 148.80M for, 22.0k against.
- Total shares represented at meeting: 148.84M out of 160.50M outstanding.

## SEC filing metadata
- accession: 0001140361-23-030932
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2023-06-22T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036123030932/0001140361-23-030932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036123030932/brhc20054672_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-030932
- JSON: https://secwatch.observer/filing/0001140361-23-030932.json
- Plain text: https://secwatch.observer/filing/0001140361-23-030932.txt

## Key facts
- Shareholder Votes
  BridgeBio Pharma, Inc. shareholders approved Election of four Class I director nominees to hold office until the 2026 Annual Meeting at the 2023-06-21 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-21
  source text: Proposal 1 - Election of Directors. The Company’s stockholders elected the four (4) director nominees below to the Company’s Board of Directors as Class I directors to hold office until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. Director Nominee Votes For Votes Withheld James C. Momtazee 126,983,947 6,964,797 Frank McCormick, Ph.D. 126,128,725 7,820,019 Randal W. Scott, Ph.D. 131,253,639 2,695,105 Hannah A. Valantine, M.D. 107,393,329 26,555,415 There were 14,889,405 broker non-votes regarding this proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036123030932/0001140361-23-030932-index.htm
- Shareholder Votes
  BridgeBio Pharma, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-21 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-21
  source text: Proposal 2 - Non-binding Advisory Vote on Compensation of Named Executive Officers. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. Votes For Votes Against Abstentions 104,001,511 29,901,611 45,622 There were 14,889,405 broker non-votes regarding this proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036123030932/0001140361-23-030932-index.htm
- Shareholder Votes
  BridgeBio Pharma, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-21 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-21
  source text: Proposal 3 - Ratification of Appointment of Independent Registered Accounting Firm. The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions 148,795,806 21,960 20,383 There were zero broker non-votes regarding this proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036123030932/0001140361-23-030932-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.